Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
The International Conference on Harmonization (ICH) agreed on the eligibility requirements for members of a newly set up ICH assembly at its meeting in Fukuoka, southwestern Japan. At the meeting, held for six days through June 11, the ICH agreed…
To read the full story
Related Article
- Q&A Document on GMP for APIs Reaches Step 4: ICH Meeting in Fukuoka
July 13, 2015
- ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
- Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
November 5, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- eCTD Progresses to Step 4 at ICH in Brussels
July 18, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
REGULATORY
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…